RNA: RNA-based therapies can protect against many types of covid: studies

Washington: Ann RNA Molecules that stimulate the body’s early antivirals Defense system Accordingly, SARS-CoV-2 can provide protection against a range of variants, including Delta Study Carried out in rats.
Ribonucleic acid (RNA) is a single molecule essential for the expression of various biological roles and genes.
Researchers at the Yale School of Medicine in the U.S. noted that the molecule could lead to new treatments. Covid-19 In patients with immunodeficiency.
The research, recently published in the Journal of Experimental Medicine (JEM), may also provide a cheaper treatment option for many developing countries that do not currently have access to the vaccine.
The study was conducted before Omicron In many countries the variant behind the current spike in the Covid-19 case was identified and not tested.
Researchers have noted that the vaccine against SARS-CoV-2 is extremely effective in preventing serious disease and death.
However, vaccine availability is extremely limited in many low-income countries, and vaccine-resistant strains of the virus are also emerging, they said.
Akiko Iwasaki, a professor at the Yale School of Medicine, said, “This is why, in addition to the use of vaccines to prevent covid-19, efforts are needed to develop effective therapies against SARS-cov-2.”
The body’s first line of defense against SARS-CoV-2 – before the involvement of antibodies and T cells – is thought to rely on receptor molecules such as RIG-I.
These molecules identify the genetic material of the virus and induce the production of a signaling protein called type I interferon.
This promotes the production of interferon proteins that can inhibit viral reproduction and stimulate the recruitment of immune cells to fight infection, the researchers said.
Multiple studies have suggested that early and strong production of interferon protects against covid-19, while delayed production is associated with severe disease.
Clinical trials have shown that treating Covid-19 patients with pure interferon protein early in the course of the disease can reduce mortality, but the production of interferon is extremely expensive.
The latest study suggests a cheaper alternative in the form of short RNA molecules that mimic the genetic material of SARS-CoV-2 and activate the RIG-I receptor to stimulate the production of type I interferons by the body’s own cells.
The researchers tested their approach in mice susceptible to SARS-CoV-2 infection.
One dose of an RNA molecule called SLR14 was sufficient to protect rats from serious disease and death, especially if treated shortly before or immediately after exposure to the virus, the researchers said.
When given SLR14 shortly after a viral infection, it was more effective than treating mice with pure interferon protein, they said. SLR14 protected rats from all emerging SARS-CoV-2 species, including delta.
Researchers tested SLR14 in rats with long-infected immunity to SARS-CoV-2.
Although RNA molecules were able to completely clear the virus from these animals, they lacked both T cells and antibody-producing B cells.
The researchers noted that RNA molecules such as SLR14 are relatively inexpensive and easy to manufacture.
“SLR14 therefore holds great promise as a new class of RNA therapy that can be applied as an antiviral against SARS-CoV-2,” Iwasaki added.


Source link

Leave a Comment